Survival by site/type of primary cancer
| Site/type of primary cancer | Time of death; no. (%*) of patients | Survival time, median (IQR), d | Crude mortality rate† (95% CI‡) | |
|---|---|---|---|---|
| Within 90 d after surgery | Within 1 yr after surgery | |||
| Breast | 62 (13.4) | 162 (35.1) | 644 (208–1225) | 32.0 (28.8–35.5) |
| Lower gastrointestinal tract | 58 (35.2) | 135 (81.8) | 132 (72–265) | 128.9 (110.2–150.3) |
| Lung | 35 (49.3) | 57 (80.3) | 95 (34–306) | 143.4 (113.0–181.9) |
| Lymphoma | 7 (13.5) | 27 (51.9) | 338 (154–2042) | 20.4 (14.5–28.7) |
| Melanoma | 46 (50.6) | 78 (85.7) | 90 (54–232) | 142.2 (115.2–175.4) |
| Myeloma | 17 (9.8) | 42 (24.3) | 830 (380–1499) | 21.5 (17.7–26.1) |
| Prostate | 62 (18.4) | 166 (49.3) | 366 (135–795) | 50.4 (44.7–56.7) |
| Thyroid | 8 (15.7) | 20 (39.2) | 906 (178–2054) | 23.0 (16.6–31.9) |
| Upper gastrointestinal tract | 21 (50.0) | (88.0–100.0)§ | 90 (34–164) | 235.3 (172.6–320.8) |
| Urinary system | 82 (28.7) | 187 (65.4) | 196 (74–614) | 78.8 (69.8–89.0) |
| Other | 308 (33.6) | 648 (70.7) | 155 (67–431) | 83.3 (77.8–89.2) |
| Overall | 706 (26.7) | 1561 (59.0) | 236 (84–740) | 55.7 (53.4–58.0) |